Surprisingly, however, neither IDO1-deficiency nor pharmacological inhibition of IDO enzymatic activity had any effect on disease parameters including serum ANA, splenomegaly, hyperactive lymphocytes, GN, and IgG-IC deposition. Here, IDO1 is linked to ganglioneuroma.